Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from ...

If you’re looking for trail shoes that are lightweight, flashy, and fun, look no more because the Arc’teryx Vertex Speed ...

The forward-looking statements contained in this Press Release are based on the expectations, estimates and projections of management of Vertex as of the date of this Press Release unless ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $492.69, signifying a -1.96% move from its prior day's close.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

For comparison, its industry has an average Forward P/E of 18.63, which means Vertex Pharmaceuticals is trading at a premium to the group. It's also important to note that VRTX currently trades at ...

Vertex Pharmaceuticals (VRTX) closed at $502.55 in the latest trading session, marking a +0.45% move from the prior day.

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...